Scholars Central

Conference abstractPublished 14 Sep 2016

Overactive bladder in the pediatric population

Authors: Stéphane Bolduc

CHU de Québec-Université Laval, Canada

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Overactive bladder (OAB) is a highly prevalent disorder in the pediatric population. This condition is especially troublesome for pediatric patients and their families when associated with incontinence since it negatively affects self-esteem and impairs children’s development. A stepwise approach is favored to treat this pathology, starting with behavioral therapy, followed by medical management, and eventually more invasive procedures. Antimuscarinic agents are the mainstay of medical treatment for OAB. Oxybutynin is the most commonly used antimuscarinic in the pediatric population. However, some patients have a suboptimal response to antimuscarinics and many experience bothersome side effects. Although there have been reports about the use of tolterodine, fesoterodine, trospium, propiverine and solifenacin in children, to date, only oxybutynin has been officially approved for pediatric in most countries. However, patients with severe OAB symptoms seem not to always respond adequately to oxybutynin. After failure with a first pharmacologic molecule, most practitioners will try a more specific anticholinergic. We have already studied various options to treat children with non-neurogenic refractory OAB, namely trying a different antimuscarinic (tolterodine, fesoterodine, or solifenacin) as well as combining two different anticholinergic. Despite favorable results with these options, they remain unapproved for pediatric use and other therapeutic avenues are therefore worth investigating. Mirabegron a new molecule with a distinct mechanism of action (β3-adrenoreceptor agonist), has recently been approved as monotherapy for idiopathic OAB in adults, but it has not been studied in the pediatric population. We recently concluded on two open-label studies to explore its efficacy and safety in children. It appears as a safe and effective alternative for children with idiopathic OAB refractory to antimuscarinics, in monotherapy or in association with antimuscarinics (add-on dual therapy). The different therapeutic alternatives reported could be included in a management algorithm for intractable OAB symptoms in children, but the need for prospective randomized controlled studies prior to official approbation is to be acknowledged.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectNephrology & Urology
  • SubjectPaediatrics & Neonatology
  • BylineArticles whose byline prints “Stéphane Bolduc”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels